Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
08/14/2017 08/15/2017 08/16/2017 08/17/2017 08/18/2017 Date
92.94(c) 92.51(c) 93.18(c) 92.76(c) 91.01(c) Last
463 728 425 849 447 123 568 787 597 460 Volume
+1.10% -0.46% +0.72% -0.45% -1.89% Change
More quotes
Financials (€)
Sales 2017 15 412 M
EBIT 2017 3 243 M
Net income 2017 1 763 M
Debt 2017 9 719 M
Yield 2017 1,39%
Sales 2018 15 731 M
EBIT 2018 3 371 M
Net income 2018 1 954 M
Debt 2018 7 652 M
Yield 2018 1,50%
P/E ratio 2017 21,88
P/E ratio 2018 19,13
EV / Sales2017 1,39x
EV / Sales2018 1,23x
Capitalization 11 762 M
More Financials
Company
Merck KGaA engages in the manufacturing of pharmaceutical and chemical products.It operates through the following segments: Healthcare, Life Science, and Performance Materials.The Healthcare segment comprises the businesses with prescription and over-the-counter pharmaceuticals and... 
Sector
Pharmaceuticals
Calendar
09/28Shareholder meeting
More about the company
Surperformance© ratings of Merck KGaA
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK KGAA
08/09 MERCK : and Baylor College of Medicine Advance Vaccine Development and Manufactu..
08/08 MERCK : NICE Recommends Erbitux® in Combination with Platinum-Based Chemotherapy..
08/07 MERCK : Presolicitation - National Centers for Environmental Health - Sigma Aldr..
08/07 MERCK : Presolicitation Notice - National Centers for Environmental Health - Sig..
08/03 DEUTSCHE BANK : Appointed Depositary Bank for Sponsored Level I American Deposit..
08/03 NANTKWEST : Announces Publication of Preclinical Data of haNK Cell Therapy in Co..
08/03 MERCK : European Patent Office to Grant Merck KGaA, Darmstadt, Germany’s P..
08/03 Q2 2017 : Merck KGaA, Darmstadt, Germany, Sets Course for Future Growth
07/31DJMERCK : 2Q 2017 -- Forecast
07/31 IMPORTER OF CONTROLLED SUBSTANCES AP : Sigma-Aldrich International GMBH
More news
Sector news : Specialty & Advanced Pharmaceuticals
08/18DJCorrection to Biogen Treads Tricky Path Between Politicians, Investors Articl..
08/18DJMERCK AND : Scientists, Out $12 Million, Sue Delaware Over Seizure of Their Stoc..
08/18DJASTRAZENECA : FDA Approves AstraZeneca's Ovarian Cancer Treatment Lynparza Table..
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/17 Drugmaker Hikma trims sales forecasts, shares fall
More sector news : Specialty & Advanced Pharmaceuticals
4-Traders Strategies on MERCK KGAA 
07/25The downward trend should continue
2016Towards the breakout of a major resistance level
More Strategies
Latest Tweets
07:16aMerck & Company's sell rating reiterated at Jefferies Group LLC. $52.00 P.. 
07:05aJefferies Keeps Their Sell Rating on Merck & Company $MRK  
08/19BLB&B Advisors LLC Continues to Hold Stake in Merck & Company, Inc. $.. 
08/19Aua Capital Management LLC Has $129,000 Position in Merck & Company, Inc... 
08/19#TodayInHealthHistory 2005: Texas jury finds @Merck liable for the death of R.. 
More tweets
Qtime:191
News from SeekingAlpha
08/17 House Dems look into MS med prices, seven drug makers contacted
08/06 Merck KGaA's (MKGAF) CEO Stefan Oschmann on Q2 2017 Results - Earnings Call T..
08/03 Merck KGaA reports Q2 results
07/06 GE and others accused of breaching EU antitrust rules
07/06 Charges over misleading merger info
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 109 €
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Michael Fletterich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-8.21%13 833
ABBVIE11.72%111 523
KYOWA HAKKO KIRIN CO LTD15.39%9 853
JAZZ PHARMACEUTICALS PLC32.44%8 673
CONVATEC GROUP22.40%7 187
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO21.75%5 043